Diacrin s.r.o.
- Address
- Jelsova 3086/1, Nove Mesto, 831 01 Bratislava, Slovakia
Cardiovascular Diseases
At Diacrin s.r.o. in Bratislava, a major focus is on cardiovascular diseases, especially atherosclerotic cardiovascular disease and related high-risk conditions. The studies are aimed at testing new approaches to lower the chance of serious heart and stroke events and to improve prevention in people with elevated cardiovascular risk.
- Evaluating new treatments for atherosclerosis and primary prevention of ASCVD
- Studying ways to reduce major cardiovascular events such as heart attack and stroke
- Comparing candidate therapies with placebo to assess protection against vascular complications
This research area reflects a strong interest in improving cardiovascular risk reduction and supporting better long-term outcomes for patients with heart and blood vessel disease.
Hormonal Diseases
The site also participates in research on hormonal diseases, with close links to conditions such as type 2 diabetes. These trials are designed to understand how new therapies may help control blood sugar and support better metabolic health in people living with chronic endocrine-related disease.
- Investigating treatments for type 2 diabetes and related glucose-control needs
- Assessing whether new medicines can improve HbA1c and overall glycemic management
- Exploring treatment effects in patients with broader metabolic disease profiles
This work helps advance more effective options for people whose health is affected by long-term hormone and metabolism disorders.
Nutritional and Metabolic Diseases
Research at this clinical trial site also includes nutritional and metabolic diseases, with studies in obesity, overweight, and chronic kidney disease. The main goal is to evaluate therapies that may improve body weight, metabolic control, and related health outcomes.
- Testing potential treatments for obesity and overweight
- Examining whether new medicines can support weight reduction and metabolic improvement
- Studying patients with chronic kidney disease alongside cardiovascular and metabolic risk
The research portfolio shows a broad effort to address interconnected metabolic disorders and their impact on overall health.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Eli Lilly & Co.1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diacrin s.r.o.
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Dose-Finding Study to Evaluate the Efficacy and Safety of Once-Weekly Subcutaneous NNC0662-0419 in Participants with Type 2 Diabetes | Novo Nordisk A/S | Phase II | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 2 | Unknown | 2023-09-04 | 2023-09-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.